Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event Peng HuangWilliam Plunkett Original Article Pages: 181 - 188
In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells—reversal of multidrug resistance by sera from phase I-treated patients Jacques SoudonMaryse BerlionFabien Calvo Original Article Pages: 195 - 203
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies Richard A. LarsonRobert B. GellerMark J. Ratain Original Article Pages: 204 - 210
Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis Jung Soo LeeToshio TakahashiShigeru Tashima Original Article Pages: 211 - 216
Antitumor activity of FCE 26644 a new growth-factor complexing molecule Francesco SolaMariella FaraoMaria Grandi Original Article Pages: 217 - 222
Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells Mary J. KuffelMatthew M. Ames Original Article Pages: 223 - 226
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia William J. SlichemyerRoss C. DonehowerEric K. Rowinsky Original Article Pages: 227 - 232
A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans Dominique Marchiset-LecaFrançois-René LecaAthanassios Iliadis Original Article Pages: 233 - 238
Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics Dominique Marchiset-LecaFrancois-René LecaJacques Catalin Original Article Pages: 239 - 243
Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide Bruce C. BaguleyLi ZhuangElaine Marshall Original Article Pages: 244 - 248
The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients F. A. MacNeillS. JacobsT. J. Powles Original Article Pages: 249 - 254
Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ cooperative group M. González-BarónJ. FeliuP. Zamora Clinical Trial Report Pages: 255 - 258
Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer C. MaulardP. RichaudM. Housset Clinical Trial Report Pages: 259 - 262
Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma Carl BlomqvistTom WiklundInkeri Elomaa Clinical Trial Report Pages: 263 - 265
Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation Hernani Robin Jr.Suresh SenanMartin A. Graham Short Communication Pages: 266 - 270
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia William J. SlichenmyerRoss C. Donehower Tian-Lingchen ORIGINAL ARTICLE Pages: 227 - 232
Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer C. MaulardP. RichaudF. Dufour-Esguerré CLINICAL TRIAL REPORT Pages: 259 - 262
